Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33

Showing 26-50 of 33 citing articles:

Therapeutic drug monitoring in inflammatory bowel disease: recent developments
Xavier Roblin, Robert D. Little, Nicolas Mathieu, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 10, pp. 575-586
Closed Access | Times Cited: 1
Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD
Kush Fansiwala, Jenny Sauk
Digestive Diseases and Sciences (2024)
Open Access | Times Cited: 1
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease
Gareth Parkes, Charlotte Hedin
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 489-491
Closed Access
Stellungnahme zur Nutzenbewertung von Etrasimod (Colitis ulcerosa, ≥ 16 Jahre)

Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 10, pp. 1857-1861
Closed Access
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn’s Disease
Jeremy Adler, Joseph A. Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology (2024)
Closed Access
The survival rate of biological therapy in immunosuppressive diseases in children
Т. В. Радыгина, С. В. Петричук, Аndrey P. Fisenko, et al.
Russian Pediatric Journal (2024) Vol. 27, Iss. 5, pp. 322-330
Open Access
Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
Thomas Chapman, Tariq Ahmad, Jack Satsangi
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 402-405
Closed Access
Reply: Predicting Adverse Events to Thiopurines in IBD: Are We a Step Closer?
Tracy Coelho, Guo Cheng, Fernando Lopez, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 10, pp. 1928-1930
Closed Access
Ultrasound transmural healing correlates with higher adalimumab drug concentration in Crohn's disease only in the short-term.
José Ramón Lorente, José María Rubio Paredes, Pilar Llopis, et al.
Revista Española de Enfermedades Digestivas (2024)
Open Access
Macrophage-Stimulating 1 Polymorphism rs3197999 in Pediatric Patients with Inflammatory Bowel Disease
Jan Brylak, Jan Krzysztof Nowak, Emilia Dybska, et al.
Medicina (2024) Vol. 60, Iss. 8, pp. 1243-1243
Open Access
Therapeutic drug monitoring for immune mediated inflammatory diseases
Neil Chanchlani, Z.Z.N. Yiu, Lisa K. Stamp, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e001130-e001130
Open Access
Impact Of Hladqa1*05 And Hladqa1*03 On Safety And Loss Of Response To Anti-Tnf In Patients With Inflammatory Bowel Disease
Julia López de la Cruz, Fernando Gomollón, Javier Louro, et al.
Journal of Crohn s and Colitis (2024)
Closed Access
Previous Page - Page 2

Scroll to top